[Intracavitary administration of recombinant interferon in cancer patients with malignant effusions].
Interferon-beta (IFN-beta), 6 X 10 units/body, was administered intraperitoneally and intrapericardially daily to five recurrent cancer patients with malignant effusion. Two of them showed complete response with a disappearance of effusion and cytological negative. However, three patients showing a decrease in effusion and cytological negative were regarded as no change because of the short duration of the response (less than four weeks). Intracavitary administrations of IFN-beta were well tolerated, and no serious side effects were observed. Autopsies showed that all intestines with disseminated metastasis maintained organic elasticity and had neither ileus-like construction nor progressive adhesions. IFN-beta showed not only anticancer effects on malignant effusion, but protection against GI tract constriction through moderate control of the growth of connective tissue.
D000368:Aged; D001202:Ascitic Fluid / Q000628:therapy*; D001943:Breast Neoplasms / Q000628:therapy*; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010529:Peritoneal Cavity; D013274:Stomach Neoplasms / Q000628:therapy*
D007370:Interferon Type I